Quince Therapeutics, Inc. (QNCX): restructuring charge — Quince Therapeutics cuts workforce 47%; reports $94M cash; pivots to in-licensing

Quince Therapeutics, Inc.

Preliminary unaudited cash, cash equivalents, and marketable securities of ~$94M as of Dec 31, 2022.
Board approved cost reduction plan cutting headcount by ~47%, expected to save ~$9.5M in annual operating expenses (2023).
Estimated restructuring costs of $0.6M–$0.8M; workforce reduction begins Feb 2023, completes by Apr 2023.
Company to prioritize in-licensing and acquisition of clinical-stage assets for rare diseases; out-license bone-targeting platform NOV004.
Out-licensing of NOV004 to commence immediately; goal to conclude partnership by end of 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Quince Therapeutics, Inc. reported preliminary financial results for the fourth quarter and year ended December 31, 2022.

Period: the fourth quarter and year ended December 31, 2022
Result: preliminary results

Exact text from the filing

The Company also reported on a preliminary and unaudited basis its estimated cash, cash equivalents, and marketable securities of approximately $94 million as of December 31, 2022.

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Quince Therapeutics, Inc. announced a restructuring with charges of approximately $0.6 million to $0.8 million (approximately 47%).

Type: restructuring
Charge: approximately $0.6 million to $0.8 million
Headcount: approximately 47%

Exact text from the filing

share-based compensation and any one-time costs related to strategic actions). In connection with the Plan, the Company estimates that it will incur expenses of approximately $0.6 million to $0.8 million, substantially all of which will be cash expenditures and other costs relating to the Plan through August 2023. The Company may incur other charges, including

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Quince Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-019103

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.